Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Humana managed to surpass the revenue expectations as well as the earnings expectations of Wall Street.</li><li>Adjusted earnings per share stood at $7.78, with notable performance in Medicaid and primary care.</li><li>Looking ahead to 2024, Humana outlined its strategic approach to Medicare Advantage, emphasizing consumer preferences and maintaining or enhancing key benefits.</li></ul>

Humana managed to surpass the revenue expectations as well as the earnings expectations of Wall Street.Adjusted earnings per share stood at $7.78, with notable performance in Medicaid and primary care.Looking ahead to 2024, Humana outlined its strategic approach to Medicare Advantage, emphasizing consumer preferences and maintaining or enhancing key benefits.

Humana Inc.: Launch of At-Home Primary Care Program & Other Developments

<ul><li>Humana Inc. delivered a solid result and managed an all-around beat in the last quarter, with adjusted earnings per share meeting expectations and positive results from all lines of business, supported by the growth in Medicare Advantage utilization.</li><li>The company has reaffirmed its full-year guidance, reflecting a significant increase in adjusted EPS over the previous year.</li><li>In this report, we have carried out a fundamental analysis of the historical financial statements of the company.</li></ul>

Humana Inc. delivered a solid result and managed an all-around beat in the last quarter, with adjusted earnings per share meeting expectations and positive results from all lines of business, supported by the growth in Medicare Advantage utilization.The company has reaffirmed its full-year guidance, reflecting a significant increase in adjusted EPS over the previous year.In this report, we have carried out a fundamental analysis of the historical financial statements of the company.

Humana Inc.: Pushing the Envelope in Member Experiences! - Major Drivers

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/asahi-intecc-co-ltd" target="_blank" data-smartkarma-citation="entities:15915:1" rel="noopener">Asahi Intecc (7747 JP)</a> is poised for multi-year growth through strong market demand for its technically superior guidewires, market leadership positioning, new product launches, and direct marketing initiatives.</li>
<li>In FY24, Asahi Intecc aims to achieve revenue of ¥100B (+11% YoY), a significant milestone. The company targets revenue of ¥110B and an operating profit margin of 23–25% in FY26.</li>
<li>Asahi Intecc is expected to be a continued beneficiary of global procedure volume recovery. The company is likely to achieve its medium-term business plan ahead of schedule.</li>
</ul>



Asahi Intecc (7747 JP) is poised for multi-year growth through strong market demand for its technically superior guidewires, market leadership positioning, new product launches, and direct marketing initiatives.
In FY24, Asahi Intecc aims to achieve revenue of ¥100B (+11% YoY), a significant milestone. The company targets revenue of ¥110B and an operating profit margin of 23–25% in FY26.
Asahi Intecc is expected to be a continued beneficiary of global procedure volume recovery. The company is likely to achieve its medium-term business plan ahead of schedule.


2024 High Conviction: Asahi Intecc (7747 JP)- Procedure Volume Recovery to Accelerate Growth

<ul><li>Humana had a healthy start to the year and managed an all-around beat in Q1.</li><li>Total medical expenses in their Medicare Advantage business for the first quarter came in a little bit better than expected.</li><li>Furthermore, the CenterWell portfolio, which consists of primary care, home care, and pharmacy, continues to experience strong growth.</li></ul>

Humana had a healthy start to the year and managed an all-around beat in Q1.Total medical expenses in their Medicare Advantage business for the first quarter came in a little bit better than expected.Furthermore, the CenterWell portfolio, which consists of primary care, home care, and pharmacy, continues to experience strong growth.

Humana Inc.: Transforming Healthcare with its CenterWell Portfolio – Key Drivers

<ul><li>Humana had a mixed quarter as its revenues were below the analyst consensus estimate but it did manage an earnings beat.</li><li>The company has fully deployed the value-based model in Virginia and North Carolina, covering over 760,000 members or 15% of Humana MA members by year's end.</li><li>Medicaid business maintained its strong performance despite lower-than-expected medical costs.</li></ul>

Humana had a mixed quarter as its revenues were below the analyst consensus estimate but it did manage an earnings beat.The company has fully deployed the value-based model in Virginia and North Carolina, covering over 760,000 members or 15% of Humana MA members by year's end.Medicaid business maintained its strong performance despite lower-than-expected medical costs.

United States

Humana Inc. is a managed health care company with medical members located in the United States and Puerto Rico.  The Company offers coordinated health care through health maintenance organizations, preferred provider organizations, point-of-service plans, and administrative services products.  Humana offers its products to employer groups, government-sponsored plans, and individuals.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Humana Inc (HUM US)

Humana Inc.: Launch of At-Home Primary Care Program & Other Developments

Humana managed to surpass the revenue expectations as well as the earnings expectations of Wall Street. Adjusted earnings per share stood at...

Baptista Research

Humana Inc.: Pushing the Envelope in Member Experiences! - Major Drivers

Humana Inc. delivered a solid result and managed an all-around beat in the last quarter, with adjusted earnings per share meeting expectations and...

Baptista Research

2024 High Conviction: Asahi Intecc (7747 JP)- Procedure Volume Recovery to Accelerate Growth

Asahi Intecc is poised for double-digit sales growth through FY26, driven by strong market demand for guidewires, market leadership positioning,...

Tina Banerjee

Humana Inc.: Transforming Healthcare with its CenterWell Portfolio – Key Drivers

Humana had a healthy start to the year and managed an all-around beat in Q1. Total medical expenses in their Medicare Advantage business for the...

Baptista Research

Humana Inc.: Major Drivers

Humana had a mixed quarter as its revenues were below the analyst consensus estimate but it did manage an earnings beat. The company has fully...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)